July 1, 2013
, (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the Company has been added to the
3000® and Russell Global® Indexes as part of Russell Investments' second-quarter IPO additions that took place after market close on
June 28, 2013
2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the
3000®, representing approximately 10 percent of the total market capitalization of that index. Membership in the
2000® Index includes automatic inclusion in the appropriate growth and style indexes.
Russell Investments determines membership for each index based on objective market capitalization rankings and style attributes. More than
in assets are currently benchmarked to the
family of indexes.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
For more information, visit
and connect with us on Twitter at
SOURCE Epizyme, Inc.